Although myasthenia gravis (MG) is reported to be one of the most common irAE in TET patients administrated with ICIs, the most serious irAE is myocarditis due to the high mortality rate.[6] Sintilimab, a fully recombinant human anti-PD-1 IgG4 monoclonal antibody, which can bind to PD-1 and then inhibit the binding of PD-1 receptors on T cells to PD-L1 on tumor cells, finally activate cytotoxic T lymphocytes and improve their antitumor activity. Here, PDCD1 is linked to myasthenia gravis.